Tafasitamab

Tafasitamab is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19[1][2].

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Research Areas >> Inflammation/Immunology

Tafasitamab induces cytotoxicity against Mino and Jeko (MCL) cell lines in an E/T ratio-dependent manner XmAb5574 increases ADCP and antiproliferative activity. Tafasitamab (XmAb5574) enhances antiproliferative apoptotic activity due to caspase-induced apoptosis[1][2]. Cell Cytotoxicity Assay[1] Cell Line: NHL cell lines and primary CLL and MCL cells by γδ T cells Concentration: Incubation Time: 2 h Result: Induced killing of NHL cell lines and primary CLL and MCL cells by γδ T cells. Cell Proliferation Assay[2] Cell Line: SU-DHL-6 cells Concentration: Incubation Time: 72 h Result: Showed potent antiproliferative effects on tumor cell. Apoptosis Analysis[2] Cell Line: SU-DHL-6 cells Concentration: 0-4 ng/mL Incubation Time: 48 h Result: Showed potent antiproliferative effects due to caspase-induced apoptosis

Tafasitamab (SC, once on Day 1, 2.5 μg/kg) inhibits lymphoma growth in disseminated BL mouse xenograft tumor models[1]. Animal Model: Disseminated Raji model[1]. Dosage: 2.5 μg/kg Administration: Tafasitamab (SC, once on Day 1, 2.5 μg/kg) Result: Showed antitumor activity in disseminated Raji model. Animal Model: Disseminated Ramos model[1]. Dosage: 10 mg/kg Administration: Tafasitamab (IV, on Days 3, 6, 10, 13, 17, and 20 at a dose of 10 mg/kg) Result: Showed antitumor activity in disseminated Ramos model.

[1]. Jung Hyun Her, et al. Tafasitamab mediates killing of B-cell non-Hodgkin's lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Mar 29.

[2]. Holly M Horton, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res